Table 1. Summary of the ability of a range of human and murine normal and malignant cell lines to utilise citrulline, argininosuccinate and arginine.
Type C |
||||||
---|---|---|---|---|---|---|
Cell designation | Species | Origin | Type Aa | Type B | AS+ | AS− |
JMF9 | Human | Skin fibroblast | + | |||
A375 | Human | Melanoma | + | |||
MEWO | Human | Melanoma | + | |||
G361 | Human | Melanoma | + | |||
B16F10b | Murine | Melanoma | + | |||
HL428 | Human | Leukaemia | + | |||
JURKAT | Human | Leukaemia | + | |||
L1210 | Murine | Leukaemia | + | |||
HeLa | Human | Cervical carcinoma | + | |||
SAos-2 | Human | Osteogenic sarcoma | + | |||
CHO | Chinese hamster | Ovary | + |
This refers to the absence of growth when twice the concentration of citrulline was added instead of arginine.
Non-human lines shaded. Type A: grow only when arginine is present; Type B: grow on arginine or argininosuccinate, but not citrulline; Type C/As+: grow on citrulline and argininosuccinate; Type C/As−: grow on citrulline, but cannot grow on argininosuccinate.